Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
No Data
TOI Transcript
The Oncology Institute, Inc. (TOI) Q1 2026 Earnings Call Transcript
Positive5-8
The earnings call demonstrates strong financial performance with improved MLR and profitability in Florida, positive growth in dispensary attachment rates, and significant free cash flow improvements. The Q&A reveals optimism about expanding health plan agreements and leveraging pharmacy networks. Although management was vague about specific health plans, the overall sentiment remains positive due to the company’s strategic growth and profitability in key markets. Despite the lack of market cap data, the positive financial and strategic developments suggest a likely stock price increase.
The Oncology Institute, Inc. (TOI) Q4 2025 Earnings Call Transcript
Positive3-13
The earnings call summary indicates a positive financial performance with increased revenue, adjusted EBITDA, and free cash flow. The company has raised its revenue and EBITDA guidance for 2025, suggesting confidence in future performance. Although there are risks and uncertainties highlighted, the overall outlook remains positive with expected profitability and cash flow positivity. The strategic initiatives, including AI enablement, are likely to drive future efficiencies. Despite the absence of a market cap, the positive financial metrics and guidance suggest a stock price increase in the 2% to 8% range.
The Oncology Institute, Inc. (TOI) Q3 2025 Earnings Call Transcript
Positive11-13
The earnings call summary and Q&A session indicate positive sentiment: strong revenue growth expectations, improved gross margins, sustainable profitability, and positive free cash flow by Q4 2025. The pharmacy business is expanding, and new contracts are expected to boost growth. Despite some unclear responses, the overall outlook is optimistic, with AI initiatives and strategic expansions. The positive impact of external changes like lower drug costs further supports this view. However, the negative cash flow and reserve adjustments are minor concerns, leading to a positive, but not strong positive, sentiment.
The Oncology Institute, Inc. (TOI) Q2 2025 Earnings Call Transcript
Positive8-13
The earnings call highlights strong financial performance with increased pharmacy revenue and improved gross margins. The Q&A section reveals positive insights on drug pricing reforms and growth in patient lives, despite some vague responses from management. Overall, the company's strategic initiatives and financial metrics suggest a positive outlook, likely boosting the stock price by 2% to 8% over the next two weeks.
TOI Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
